Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) results from the loss of erythrocyte surface proteins, leading to complement activation and its spectrum of effects. We explore this case of a 57‐year‐old man with post‐essential thrombocythemia (ET) myelofibrosis (MF) who developed symptomatic anem...

Full description

Bibliographic Details
Main Authors:	Mahija Cheekati, KarLeung Siu, Rachel Ochs
Format:	Article
Language:	English
Published:	Wiley 2024-04-01
Series:	eJHaem
Subjects:	CALR case report myelofibrosis PNH thrombocythemia
Online Access:	https://doi.org/10.1002/jha2.892

Similar Items

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01)

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective studyResearch in context
by: Danhong Xiang, et al.
Published: (2024-01-01)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
by: Lasse Kjær, et al.
Published: (2023-05-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
by: Magda Zanelli, et al.
Published: (2024-03-01)

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations
by: Oliver M, et al.
Published: (2023-12-01)

COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria
by: Adam Hines, et al.
Published: (2021-08-01)

The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis
by: Yuxia Pan, et al.
Published: (2022-12-01)

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
by: Zehra Narlı Özdemir, et al.
Published: (2024-03-01)

Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation
by: Ferras Alashkar, et al.
Published: (2020-09-01)

Eculizumab for paroxysmal nocturnal hemoglobinuria: Two cases of successful pregnancy outcomes
by: Jovanka Ilic, et al.
Published: (2024-05-01)

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
by: Keiji Minakawa, et al.
Published: (2021-03-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia
by: Zhuanghui Hao, et al.
Published: (2024-01-01)

Paroxysmal nocturnal hemoglobinuria‐phenotype cells predict a good response to eltrombopag in patients with refractory aplastic anemia
by: Ken Ishiyama, et al.
Published: (2020-07-01)

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RECOMMENDATIONS FOR DIAGNOSIS AND EXAMINATION OF THE PATIENT POPULATION IN SLOVENIA
by: Jasmina Hauptman, et al.
Published: (2016-10-01)

VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
by: Laura Villani, et al.
Published: (2021-10-01)

Invasive ductal breast carcinoma preceded by CALR‐positive essential thrombocythemia
by: Elrazi A. Ali, et al.
Published: (2021-03-01)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
by: İpek Yonal, et al.
Published: (2016-05-01)

Paroxysmal nocturnal hemoglobinuria in a patient post COVID‐19 virus infection: A case report with literature review
by: Mohammed Albalawi, et al.
Published: (2023-10-01)

A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ
by: R. Paola Daly, et al.
Published: (2021-09-01)

Molecular study of CALR gene mutations in children with leukemia hospitalized in Kerman hospitals
by: Farzaneh Parnak, et al.
Published: (2020-03-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
by: Mostafa Najim, et al.
Published: (2024-12-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuria
by: Marek Ussowicz, et al.
Published: (2025-01-01)

A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients
by: Uzma Zaidi, et al.
Published: (2020-03-01)

Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia
by: Ragousandirane Radjasandirane, et al.
Published: (2023-03-01)

Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry
by: Margarida Lima
Published: (2020-05-01)

A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria
by: Abdülkerim Yıldız, et al.
Published: (2014-08-01)

Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis
by: Ruby Sharma, et al.
Published: (2015-01-01)

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives
by: Massimo Breccia, et al.
Published: (2024-07-01)

Case Report: Effects of multiple myeloma therapy on essential thrombocythemia and vice versa: a case of synchronous dual hematological malignancy
by: Nupur Krishnan, et al.
Published: (2023-06-01)

Paroxysmal nocturnal haemoglobinuria, diagnosis and haematological findings, first report from Iran, model for developing countries
by: Mohammadali Jahangirpour, et al.
Published: (2022-05-01)

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations
by: Ana Guijarro-Hernández, et al.
Published: (2023-08-01)

Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
by: Di Matteo S, et al.
Published: (2024-04-01)

Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review
by: Saito M, et al.
Published: (2020-07-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
by: Giuseppe G. Loscocco, et al.
Published: (2021-08-01)

Normalisation of haemoglobin and control of breakthrough haemolysis with increased frequency pegcetacoplan dosing in treated paroxysmal nocturnal haemoglobinuria
by: Amanda K. Davis, et al.
Published: (2023-08-01)